Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
4,801 total articles
Credo Technology's sharp pullback cleared froth near the 52-week high and left a high-conviction entry zone. Strong fundamentals - triple-digit revenue growth, positive free cash flow and a clean balance sheet - back a long trade with clear stop placement and two realistic upside targets. This is a mid-term trade (45 trading days) with defined risk…
LATAM has emerged from restructuring as a leaner, more profitable airline. Improved unit economics, a large 787 buildout and a still-recovering South American demand backdrop justify an upgrade to Strong Buy. Trade plan: enter at $64.82, target $80, stop $58, horizon 46-180 trading days.
Paylocity is trading near its 52-week low after a sharp pullback. Valuation looks reasonable versus growth profile: market cap about $6.1B, P/E ~25, EV/EBITDA ~14 and free cash flow of roughly $461M. Low leverage and a string of product and partnership catalysts make a tactical long attractive with a defined risk plan targeting a bounce back to $14…
Hugo Boss (BOSSY) trades at modest multiples with a meaningful dividend yield and room for margin recovery. Current technicals are constructive but not stretched. This trade idea recommends waiting for a defined pullback to $7.50 as the best risk/reward entry for a long position into key 2026 operational catalysts; stop at $6.80, target $10.00 over…
Super Micro (SMCI) just demonstrated it can scale at AI speed - Q2 sales jumped to $12.68B and management now points to at least $40B for fiscal 2026. That growth sets up a high-conviction swing trade on a breakout, but compressed gross margins and customer concentration make this a high-risk, high-reward idea. Entry $34.50, stop $30.00, target $50…
Tejon Ranch (TRC) offers exposure to California master-planned development optionality at a sub-$500M market cap. With entitlements, a recent industrial JV, supportive local leaders and a balance sheet that is light on debt, TRC looks attractive as a long-term trade that pays to front-run value realization from commercial and mixed-use projects.
Olympic Steel (ZEUS) is a small-cap, cash-generative steel processor whose pending stock-for-stock merger with Ryerson has drawn activist and plaintiff-lawyer attention. That attention raises the odds of a negotiated bump to consideration or added disclosure that could re-rate the stock from its bargain EV/sales and unlock 15-25% upside. Fundamenta…
RTX has momentum from a hefty $260 billion backlog, double-digit revenue growth and improving free cash flow, but the stock is extended. This trade idea maps a disciplined dip-buy: enter at $175.00, stop at $165.00, and target $215.00 over a 45 trading-day swing. The set-up balances a favorable fundamental backdrop against near-term technical fatig…
Palantir's platforms sit squarely in the path of enterprise adoption of agentic AI (AIP). With strong revenue growth in government and commercial segments, solid free cash flow and low balance-sheet leverage, the company is well positioned to monetize deeper AI workflows. At current prices the stock is richly valued, so this trade uses a discipline…
Patria reported record 2025 fundraising and a string of accretive acquisitions that materially increase Fee-Earning AUM across credit, real estate and private markets. At a market cap of roughly $2.3 billion, the stock looks priced for modest growth; we think incremental FRE and visible M&A re-rating could drive PAX back toward its 52-week high. Tr…
Kohl's (KSS) is a beaten-down department store with clear structural problems, but recent data show the pace of comparable-store sales decline slowed in 2025. The shares trade at single-digit price-to-book and low EV multiples, free cash flow is meaningful, and short interest remains elevated. For nimble traders willing to accept volatility, a mid-…
Twist Bioscience looks positioned to ride accelerating demand for next-generation sequencing (NGS) and liquid biopsy applications — especially minimal residual disease (MRD) testing — while efficiency gains have started to show in GAAP results. The balance of high valuation and improving fundamentals creates an opportunistic, risk-managed long trad…
Arch Capital (ACGL) has pulled back into the mid-$90s on heavy volume and short-selling, but fundamentals - low leverage, strong free cash flow ($6.295B), and attractive valuation (PE ~8.6, P/B ~1.47) - argue for a tactical long. This trade idea lays out an entry at $96.03, a stop at $86.00 and a primary target of $110.00 over a 180-trading-day hor…
WPP is trading at bargain multiples after a painful share-price correction. At $18.66 the stock carries an elevated yield and single-digit P/E that imply free-cash-flow generosity; combine that with secular digital ad growth and the potential for operational stabilization and you have an asymmetric trade. This is a long idea with a defined entry, s…
DBS Group (DBSDY) offers a balanced trade: a reliable dividend (3.7% yield), a sensible P/E (~15.8) and exposure to Asia's recovery. Technicals are mixed but constructive; we lay out an entry at $183.09, a $205 target and a $170 stop for a long-term (180 trading days) swing that captures both income and capital appreciation.
CrowdStrike (CRWD) remains the market leader in cloud-native endpoint and workload protection. After a pullback that left technical indicators oversold, the stock offers a better entry for traders who want exposure to high-growth cybersecurity without paying peak multiples. This trade idea lays out an actionable mid-term long: entry at the current …
Medpace reported robust growth and cash flow, but the stock is trading at a premium (PE ~36, EV/EBITDA ~28) after a strong rerating. With technicals weak and evidence that bookings/backlog are not accelerating enough to justify the multiple, a structured short against $535 with a $460 target over the next 45 trading days offers a defined risk/rewar…
Cenovus ($CVE) completed the MEG Energy acquisition and added ~110,000 bbl/d of low-cost oil sands production. The company is guiding modest 2026 upstream growth, has a refreshed buyback program, and is refinancing debt. Technical momentum is bullish. This trade idea buys the name on strength with a defined stop and a clear mid-term horizon tied to…
Genworth is trading at steep discounts to book and to obvious intrinsic components. Enact mortgage insurance continues to generate earnings and capital returns while long‑term care exposure is de‑risking through rate actions. With a market cap near $3.55B, EV of roughly $3.09B and EV/EBITDA under 4, this is a deep‑value sum‑of‑the‑parts opportunity…
Allegiant's cost-focused model and the accretive Sun Country deal give the stock a clear re-rating path. Catalyst-driven swing trade with defined entry, stop and target: capture merger optimism, early synergy proof points and continued leisure demand while respecting balance-sheet and valuation risks.
Dominion Energy is uniquely exposed to Virginia's data-center boom and is pressing forward on the Coastal Virginia Offshore Wind (CVOW) project despite a short-lived federal review. The business mix, dividend yield, and reasonable valuation support a measured long trade over the next 45 trading days while watching regulatory signals and cash-flow m…
Intuit has been punished with the rest of software as investors fear AI will replace SaaS economics. The selloff has left a high-quality franchise trading at roughly half its 52-week high, with healthy free cash flow, low net leverage, and an oversold technical picture. This trade idea grades Intuit attractive now for a position trade with explicit…
Solid Biosciences looks positioned to re-rate after a positive FDA interaction on SGT-003 and a string of regulatory wins for the gene-therapy space. With a market cap near $533M, manageable enterprise value and clear catalysts ahead, we prefer a tactical long with defined risk control.
Hims & Hers (HIMS) plunged to 52-week lows after an FDA crackdown and a patent suit from Novo Nordisk over compounded semaglutide pills. The sell-off created a high-conviction trade: buy the oversold dip around $19.33 with a tight stop under the intraday low and a mid-term target near $28. The company still has a $4.4B market cap, positive free cas…
Novo Nordisk (NVO) has been hit hard after weaker 2026 guidance and a U.S. pricing deal, but its GLP-1 demand and new oral pill adoption give a clear rebound scenario. This trade idea lays out a mid-term swing entry, explicit stop and target levels, catalysts to watch, and the risks that could invalidate the trade.
